180 likes | 360 Views
Objectives of Work Package 5 objectives for today. Information on centres of expertise for rare cancers. WP leader: Sabine Siesling. Aim To identify the qualification criteria for centres Centres of Expertise ( CoE ) for rare cancers Deliverable (No: 7)
E N D
Objectives of Work Package 5 objectives for today • Information on centres of expertise for rare cancers WP leader: Sabine Siesling
Aim To identify the qualification criteria for centres Centres of Expertise (CoE) for rare cancers Deliverable (No: 7) Report identifying criteria indicating the level/quality of expertise for rare cancers management Work Package 5
Milestones ‘Consensus’ meeting on criteria CoE (today) A protocol for the high resolution study Data collection (cancer registries) and analysis Meeting to discuss the results Final dissemination meeting with experts held/report > spring 2014 Milestones
How? • with a wide consensus process • high resolution studies • feedback/discussion on the results Together with partners, collaborators, clinicians, patients, scientific societies, health authorities
High resolution study • Study with detailed data on i.e. stage and treatment • Answering more in depth questions • More than the “general” epidemiological / public health study questions (incidence, mortality, survival, prevalence) • Possible already gathered in the cancer registry or available but still needs to be registered
Associated partner: INT, ISS, UEDIN, ECPC, NOH, NCR, CSF, OILJ Collaborating partners: RCE (Rare cancers Europe), EPAAC, ESSO, ESO, INSERM (Orphanet), Centre of Leon Bernard, ESMO, LeukaNet, ECCO Experts (clinicians and patient groups) for selected tumour types! Partners WP5
Criteria for CoE • General criteria > all rare tumour types • Specific criteria > selection of tumour types
General criteria for CoE on all rare diseases available European Union Committee of Experts of rare diseases (EUCERD) Multidisciplinary scientific society Patient organizations Policy makers General criteria for CoE
Possible general criteria for CoE (EUCERD): 1) the attractiveness measured through the volume of cases treated (relation to WP4), 2) the capacity to produce and adhere to clinical guidelines (i.e. staging procedure and treatment), 3) outcomes (i.e. surgical free margins, number of revision surgery, survival and recurrence),
Possible general criteria for CoE (EUCERD): 4) the availability of multidisciplinary team, 5) the collaboration with other centers of expertise at national and international level (also for clinical trials). 6) capacity to participate in data collection (clinical research and public health in relation to CR)
Specific criteria for CoE and High Resolution Studies Only for a selection of rare cancer types Rationale: • Expected difference in clinical management (adherence to guidelines) • Expected difference in clinical outcome • Geographical patterns (risk factors) and trends in incidence • Already work done by other groups • Not extremely rare
Four groups of rare tumours we focus on; Sarcomas Testicular cancer Neuroendocrine tumours Head And Neck Tumours Specific criteria for CoE and High Resolution Studies
Develop tumour specific indicators for CoE on specific rare tumours preferably based on guidelines All experts involved in diagnostics and treatment for specific tumour Pathology, medical oncology, surgery, radiotherapy, patient advocacy groups Criteria for expert groups to develop specific indicators
Objectives of meeting today 1. A list of the main issues per tumour site 2. The way forward to come to indicators
1. A list of the main issues per tumor site • Document circulated with proposal • Presentation of key-note 20-25 minutes • What is very important for this specific cancer? • Are there disparities to be expected between hospitals? • Can we identify centres of excellence with main issues? • Are there main issues lacking? • How is the view of the patient? • Proposal of most important issues?
2. The way forward to come to indicators • Continuation of todays meeting • High detailed analysis • Collaboration with other parties for dissemination of results • EORTC/OECI • Role of scientific society • Role of patients • Who else should be involved?